Annovis Bio, Inc., a biotechnology company headquartered in Berwyn, Pennsylvania, has recently provided an update on its ongoing clinical trials and financial performance. As a company specializing in the development of treatments for Alzheimer’s and Parkinson’s diseases, Annovis Bio is making significant strides in its research efforts, particularly with its investigational drug, buntanetap.
In a current report filed on May 15, 2026, Annovis Bio summarized its first-quarter results for the period ending March 31, 2026. A key highlight from the report is the progress of its Phase 3 Alzheimer’s disease trial. The company has successfully achieved 85% of its target enrollment, with full enrollment expected by the summer of 2026. This milestone sets the stage for the anticipated release of top-line data in early 2027. The trial’s success is a testament to Annovis Bio’s commitment to addressing the urgent need for effective Alzheimer’s treatments.
In parallel, the company’s Parkinson’s disease open-label extension trial has reached 40% enrollment, with completion projected for the fourth quarter of 2026. This trial is part of Annovis Bio’s broader strategy to explore the potential of buntanetap in treating Parkinson’s disease, alongside its primary focus on Alzheimer’s.
Financially, Annovis Bio reported a cash balance of $14.2 million as of the end of the first quarter, a decrease from $19.5 million a year earlier. This reduction reflects the company’s increased investment in research and development, which rose sharply to $16.7 million for the quarter. Despite these investments, the company recorded a net loss per share of $0.63 for the quarter, compared to $0.32 in the prior year. These figures underscore the financial challenges inherent in the biotechnology sector, where substantial R&D expenditures are often necessary to advance clinical trials and bring new therapies to market.
Looking ahead, Annovis Bio has outlined its plans to file a new drug application for buntanetap as a symptomatic treatment for Alzheimer’s disease in early 2027. The company is also exploring the potential of buntanetap as a disease-modifying therapy, with plans to pursue this application in early 2028. These steps represent critical milestones in Annovis Bio’s journey to bring innovative treatments to patients suffering from these debilitating diseases.
As Annovis Bio continues to navigate the complexities of drug development, its focus remains on delivering meaningful advancements in the treatment of Alzheimer’s and Parkinson’s diseases. The company’s efforts are closely watched by investors and healthcare professionals alike, as the potential impact of buntanetap could be transformative for patients and their families. For more information on Annovis Bio’s activities and developments, interested parties can visit their website at www.annovisbio.com .
